STRATA Secures CMS Partnership and Q2 Filings Fuel Stock Surge

Introduction

STRATA Skin Sciences Inc. (NASDAQ: SSKN) is an American medical technology company that specializes in non-invasive phototherapy devices for dermatologic conditions. The company’s flagship product, XTRAC®, delivers a targeted UVB beam to treat psoriasis and vitiligo. Other products include the TheraClear®X system for mild-to-moderate acne and the VTRAC™ Excimer Lamp System.

Corporate Structure

Headquartered in Horsham, Pennsylvania, STRATA Skin Sciences was founded in 2016. The company employs between 51 and 200 people and is led by President and CEO Dr. Dolev Rafaeli. STRATA’s research, development, and commercial operations are supported by a direct sales force and strategic partnerships.

Phototherapy by Dan Meyers

Recent Developments and News

• August 14, 2025: STRATA filed Form 10-Q for the quarter ended June 30, 2025, detailing second-quarter operational and financial results.
• August 18, 2025: The company filed Form 8-K reporting items 7.01 (regulation FD disclosure) and 9.01 (financial statements and exhibits).
• August 22, 2025: STRATA filed Form 8-K under item 3.01 to report material agreements and events.
• August 2025: The company announced a collaboration with the Centers for Medicare & Medicaid Services (CMS) to secure temporary reimbursement codes for XTRAC® excimer laser treatments, set for implementation on January 1, 2027. This initiative aims to extend coverage potentially to over 30 million Medicare beneficiaries.
• August 2025: STRATA observed Psoriasis Awareness Month and cited data from the American Academy of Dermatology indicating that 84 percent of patients achieved at least 75 percent clearance after ten or fewer treatments with XTRAC®.

Financial and Strategic Analysis

As of September 2, 2025, STRATA’s shares closed at $3.6499, reflecting a 53.36 percent increase year-to-date, on a trading volume of 9,181,263 shares. The August 14 10-Q filing provides details on revenue and expense metrics for the first half of 2025, while the August 18 and 22 8-K filings include significant corporate disclosures and agreements. The company is focusing on expanding reimbursement pathways and securing CE Mark approval for MelaFind in the European Union, while integrating its phototherapy platforms into dermatology practice protocols.

Market Position and Industry Context

STRATA operates in the medical equipment manufacturing sector, targeting dermatologists and outpatient clinics. The global phototherapy market is expanding as healthcare providers seek non-drug treatment options for conditions such as psoriasis, vitiligo, and atopic dermatitis. XTRAC® is FDA-cleared as the only excimer laser approved for these indications, positioning STRATA alongside traditional UV booths and systemic therapies. Ongoing efforts to secure Medicare reimbursement codes by 2027 are aimed at enhancing device utilization and driving market penetration.

TL;DR

In August 2025, STRATA Skin Sciences filed its Q2 2025 10-Q and two 8-K reports, and entered a collaboration with CMS to obtain temporary Medicare reimbursement codes for XTRAC® ahead of the January 1, 2027 rollout. As of September 2, 2025, the stock trades at $3.65, up 53.36 percent year-to-date. The company’s focus on expanded coverage and phototherapy innovation aims to broaden patient access and support revenue growth through 2027.